



CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING  
DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST-  
CLASS MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER OF  
PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450, ON

22 SEPTEMBER 2003

Gene H. Halata  
NAME OF PERSON MAILING DOCUMENT

9/22/03  
DATE

Attorney Docket No. P30693C4X1C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: MacPhee, et al. 22 September 2003  
Serial No.: 09/922,067 Group Art Unit No.: 1652  
Filed: 03 August 2001 Examiner: Manjunath N. Rao  
For: Lipoprotein Associated Phospholipase A2, Inhibitors Thereof and Use of the  
Same in Diagnosis and Therapy

Commissioner of Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

**TERMINAL DISCLAIMER UNDER 37 C.F.R. § 1.321(b)/(c)**


Petitioner, SmithKline Beecham p.l.c., New Horizons Court, Brentford, Middlesex TW8 9EP, England, represents that it is the assignee of all title and interest in United States Patent Application Serial No. 09/922,067, filed on 03 August 2001, for "Lipoprotein Associated Phospholipase A2, Inhibitors Thereof and Use of the Same in Diagnosis and Therapy", which is a Continuation Patent Application (CPA) of Application Serial Number 09/193,130, filed 28 November 2000, now abandoned, which is a Continuation of Application Serial Number 09/193,130, filed on 17 November 1998, now abandoned, which is a Continuation of Application Serial Number 08/387,858, filed 24 February 1995, now granted under U.S. Patent Number 5,981,252, and allowed on 09 November 1999, which is a §371 of International Application Number PCT/GB94/01374, filed 24 June 1994, which claims priority to Great Britain Application Number GB 9313144.9, filed 25 June 1993, and GB 9400413.2, filed 11 January 1994 for "Lipoprotein Associated Phospholipase A2, Inhibitors Thereof and Use of The Same in Diagnosis and Therapy" by virtue of the assignment in said United States Patent Application Serial Number 08/387,858, said

assignment being duly recorded at Reel 7477 and Frame 0286 in the United States Patent and Trademark Office on 24 February 1995. Petitioners submit that the evidentiary documents have been reviewed and certify to the best of their knowledge and belief that title is in the Petitioner seeking to take this action.

Petitioner, SmithKline Beecham p.l.c., hereby disclaims the terminal part of any patent granted on the above-identified application which would extend beyond the expiration date of United States Patent Number 5,981,252, and hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to United States Patent Number 5,981,252. Petitioner does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term of United States Patent Application Number 5,981,252 in the event that United States Patent Number 5,981,252 is abandoned, expires for failure to pay a maintenance fee, is held disclaimed in whole or terminally disclaimed under 37 C.F.R. §1.321(a), has all claims canceled by reexamination certificate, or is otherwise terminated prior to the expiration of its statutory term, except for the separation of legal title as stated above. This disclaimer shall not be effective against any patent term extensions obtained under 35 U.S.C. §156 for any patent granted on the above-identified application. This terminal disclaimer shall run with any patent granted on the above-identified application and shall be binding upon the grantee, its successors or assigns.

Please charge the \$110.00 fee required by this Petition under 37 CFR 1.20(d) to Deposit Account Number 19-2570. Two copies of this form are enclosed. Also, should the Commissioner determine that said fee is not sufficient to have the petition entered, the Commissioner is hereby authorized to charge any such fee that may be required by this petition or to credit any overpayment to said deposit account.

Respectfully submitted



Andrea V. Lockenour  
Attorney of for Applicants  
Registration No. 51,962

GlaxoSmithKline  
Corporate Intellectual Property-U.S.  
Mailcode UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
(610) 270-7568 - telephone  
(610) 270-5090 - facsimile  
N:\HAN\APPS\IP30693-C4\X1C1 Term Disc.doc